Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalamine for colorectal neoplasia prevention in Lynch syndrome
2016-003548-35Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in colon neoplasm and colorectal cancer (CRC) comparing Mesalamine with Placebo (2 arms). Primary endpoint: Occurrence of any colorectal neoplasia. Started Mar 2017; status: terminated.
02
Drugs
Salcrozine
03
Conditions
colon neoplasmcolorectal cancer (CRC)
Beyond the preview
Go deeper on 2016-003548-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003548-35.